Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
-
Published:2021-12-18
Issue:
Volume:
Page:
-
ISSN:1170-7690
-
Container-title:PharmacoEconomics
-
language:en
-
Short-container-title:PharmacoEconomics
Author:
Spelman Timothy, Herring William L., Zhang Yuanhui, Tempest Michael, Pearson Isobel, Freudensprung Ulrich, Acosta CarlosORCID, Dort Thibaut, Hyde Robert, Havrdova Eva, Horakova Dana, Trojano Maria, De Luca Giovanna, Lugaresi Alessandra, Izquierdo Guillermo, Grammond Pierre, Duquette Pierre, Alroughani Raed, Pucci Eugenio, Granella Franco, Lechner-Scott Jeannette, Sola Patrizia, Ferraro Diana, Grand’Maison Francois, Terzi Murat, Rozsa Csilla, Boz Cavit, Hupperts Raymond, Van Pesch Vincent, Oreja-Guevara Celia, van der Walt Anneke, Jokubaitis Vilija G., Kalincik Tomas, Butzkueven Helmut, Spelman T, Havrdova E, Horakova D, Trojano M, Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand’Maison F., Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis V. G., Kalincik T, Butzkueven H,
Funder
Biogen International GmbH
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|